Newsletter Login



Need help logging in?

New Subscriber?
Start Here!

30 Day Trial!

Activate Trial

Welcome to Dow Theory Forecasts

Dow Theory Forecasts is written with the busy reader in mind. Weekly stock recommendations and analysis is geared towards the individual investor looking for actionable stock market advice in a "just-the-facts" approach. Twice weekly hotlines with market news, stock upgrades and downgrades keep subscribers informed between issues.

View back issues in the Dow Theory Archive.

From the Current Newsletter:

December 22, 2014 issue

Big U.S. firms flush with cash

Strong corporate profits have helped S&P 500 nonfinancial companies stuff their balance sheets with $1.4 trillion in cash, up 19% from three years ago and equal to about 9% of their combined stock-market value.

No sector is more flush than technology, which holds $508 billion in cash, 36% of the total for the index’s...

Read the rest of this article for more specific investing advice and stock investment information when you sign up for a FREE 30-day trial to Dow Theory Forecasts.

More Investment Newsletters and Services

Drip Investor

DRIP Investor — how you can buy dividend-paying stocks without a broker.

Visit us at DRIP Investor, your source for dividend reinvestment plans.

Lazy Investor

The Lazy Investor — free weekly e-letter that delivers market updates and stock market information via email.

Visit us at The Lazy Investor, our free investment newsletter.

Horizon Investment

Horizon — registered investment advisor seeks to provide investors at all stages the ability to build, preserve and enjoy wealth.

Visit us at Horizon Investment Services to get started in an investment program that's right for you.


Upside — discovers today's small and midcap stocks poised to be tomorrow's Blue Chip leaders.

Visit us at Upside, your guide to the best buys in small and midcap stocks.

Current Hotline

Friday, December 19, 2014

It took seven trading days for the Dow Industrials to fall 5% from their all-time high of 17,958.79 reached Dec. 5

Read More from the Hotline

Stock Spotlight

Drugmaker Mylan far from generic

Wednesday, December 17, 2014

We dropped generic-drug maker Mylan ($54; MYL) from the Focus, Buy, and Long-Term Buy lists last December because of eroding Quadrix scores and softening revenue...

Read More from Stock Spotlight

Individual Stock Reports

ISRs make stock research easy!

Perhaps the most valuable two page reports available anywhere.

All the data you would normally have to plow through years of 10-K filings, earnings reports, and reams of market data to assemble — yours all in one concise report.

ISRs contain our proprietary Quadrix scores — find out how we rate all the stocks in the S&P 500.

Visit us at